SEARCH:   Advanced

Blood, 15 August 2005, Vol. 106, No. 4, pp. 1240-1245. Prepublished online as a Blood First Edition Paper on April 28, 2005; DOI 10.1182/blood-2004-12-4975. This Article Full Text Full Text (PDF) All Versions of this Article: 2004-12-4975v1 106/4/1240    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Han, S. Y. Articles by Lee, S. Y. Search for Related Content PubMed PubMed Citation Articles by Han, S. Y. Articles by Lee, S. Y. Related Collections Hematopoiesis and Stem Cells Signal Transduction Gene Expression Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  HEMATOPOIESIS Transcriptional induction of cyclooxygenase-2 in osteoclast precursors is involved in RANKL-induced osteoclastogenesis Song Yi Han, Na Kyung Lee, Kyung Hee Kim, In Whan Jang, Mijung Yim, Jae Hong Kim, Won Jae Lee, and Soo Young Lee From the Division of Molecular Life Sciences and Center for Cell Signaling Research, Ewha Womans University, Seoul, Korea; College of Pharmacy, Sookmyung Women's University, Seoul, Korea; and School of Life Sciences and Biotechnology, Korea University, Seoul, Korea. Regulation of osteoclast differentiation is key to understanding the pathogenesis and to developing treatments for bone diseases such as osteoporosis. To gain insight into the mechanism of the receptor activator of nuclear factor (NF)–B ligand (RANKL)–specific induction of the osteoclast differentiation program, we took a suppression-subtractive hybridization screening approach to identify genes specifically induced via the RANKL-Rac1 signaling pathway. Among identified targets, we show that RANKL selectively induces cyclooxygenase (COX) 2 expression via Rac1 that results in turn in production of prostaglandin E2 (PGE2) in RAW 264.7 cells. By using transient transfection assays, we found that the –233/–206 region of the COX-2 promoter gene was critical for RANKL-induced promoter activity. This RANKL-responsive region contained an NF-B site that, when mutated, completely abolished the induction of NF-B DNA-binding activity by RANKL. Blockade of COX-2 by celecoxib inhibits differentiation of bone marrow-derived monocyte/macrophage precursor cells (BMMs) into tartrate-resistant acid phosphatase-positive (TRAP+) osteoclastic cells. This inhibition can be rescued by the addition of exogenous PGE2, suggesting that COX-2–dependent PGE2 induction by RANKL in osteoclast precursors is required for osteoclast differentiation. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Cox-2 RANKs high in osteoclastogenesis Elizabeth Olmsted-Davis Blood 2005 106: 1144-1145. [Full Text] [PDF] This article has been cited by other articles: H. Namazi Practice Pearl: A Novel use of Botulinum toxin for Unicameral Bone Cyst Ablation Ann. Surg. Oncol., February 1, 2008; 15(2): 657 - 658. [Full Text] [PDF] B. Hoang, L. Zhu, Y. Shi, P. Frost, H. Yan, S. Sharma, S. Sharma, L. Goodglick, S. Dubinett, and A. Lichtenstein Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance Blood, June 1, 2006; 107(11): 4484 - 4490. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020